Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Horowitz Encourages Industry to Participate in Supply Chain Pilots

This article was originally published in The Gold Sheet

Executive Summary

Get involved in supply chain pilots urges FDA's Horowitz in remarks at Georgia GMP conference. As imports grow, FDA is responding with 'paradigm shift.' Secure supply chain pilot program described. Industry responds with call for greater flexibility. Third-party food certification program launched. Draft guidance proposes good importer practices. Drug makers respond with 'Green Lane' proposal. New authorities in Globalization Act described.

You may also be interested in...



Firms That Get Complete Response Letters Might Get Inspected By US FDA Six Months After Replies

While COVID-19 continues to wreak havoc on FDA's ability to perform onsite preapproval inspections, new guidance offers some clarity, but the news isn't great for ANDA holders.

COVID-19 Spurs WHO To Revise Guidance On Technology Transfers

The WHO proposes to revise 2011 guidance on technology transfers to ease the hand-off of COVID-19 drugs and vaccines from research and development facilities to commercial sites.

Nitrosamine Testing Policy From European Pharmacopeia’ Largely Aligns With USP

Two groups have issued largely complementary testing methods for measuring nitrosamine impurities in drugs, and the differences that do exist are “insignificant,” EDQM official advises. The two are working to further harmonize testing standards, given the global scope of the nitrosamine scare.

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel